The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - Abbvie; AstraZeneca; Bayer Yakuhin; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shire; Taiho Pharmaceutical; Takara Bio; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca; Baxter; Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly; NanoCarrier; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Kenta Motomura
No Relationships to Disclose
 
Izumi Ohno
Consulting or Advisory Role - Merck Serono
Speakers' Bureau - Taiho Pharmaceutical
 
Manabu Morimoto
No Relationships to Disclose
 
Satoru Seo
No Relationships to Disclose
 
Yoshiyuki Wada
No Relationships to Disclose
 
Shinpei Sato
No Relationships to Disclose
 
Tatsuya Yamashita
Speakers' Bureau - Bayer; Eisai
 
Masayuki Furukawa
No Relationships to Disclose
 
Takeshi Aramaki
No Relationships to Disclose
 
Seijin Nadano
No Relationships to Disclose
 
Kazuyoshi Ohkawa
Speakers' Bureau - Bayer; Daiichi Sankyo; Eisai; Gilead Sciences
Research Funding - Daiichi Sankyo
 
Hirofumi Fujii
No Relationships to Disclose
 
Toshihiro Kudo
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer Yakuhin
Research Funding - Bayer Yakuhin; Chugai Pharma; Lilly; Ono Pharmaceutical; Yakult Honsha
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Hiroki Takai
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Gosuke Homma
Employment - Lilly Japan
 
Reigetsu Yoshikawa
Employment - Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Sanofi
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)